Tebentafusp
- Generic Name
- Tebentafusp
- Brand Names
- Kimmtrak
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1874157-95-5
- Unique Ingredient Identifier
- N658GY6L3E
- Background
Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of interest and re...
- Indication
Tebentafusp is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
- Associated Conditions
- Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
- Associated Therapies
- -
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 30
- Registration Number
- NCT06627244
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Adjuvant Tebentafusp in High Risk Ocular Melanoma
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 290
- Registration Number
- NCT06246149
- Locations
- 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇵🇱Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
🇫🇷Institut Curie - Hôpital de Paris, Paris, France
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Diwakar Davar
- Target Recruit Count
- 44
- Registration Number
- NCT06070012
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT05549297
- Locations
- 🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇩🇪Charité - Campus Charité Mitte, Berlin, Germany
🇩🇪Universitaetsklinikum Erlangen, Erlangen, Germany
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 850
- Registration Number
- NCT05315258
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust (Screening only), Cambridge, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
- Conditions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Immunocore Ltd
- Registration Number
- NCT04960891
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.